文献速递皮肤感染

印度毛癣菌:流行病学、抗真菌耐药与抗真菌药物管理策略

Trichophyton indotineae: Epidemiology, antifungal resistance and antifungal stewardship strategies.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-07-04

本范围综述汇总印度毛癣菌的临床与实验室评估,概述其流行病学、临床表现、诊断方法、抗真菌敏感性模式、耐药机制及管理策略。该菌对特比萘芬耐药与角鲨烯环氧化酶单核苷酸变异相关,分子诊断是区分同复合群菌种的必要手段。文献强调需改善诊断可及性、合理处方抗真菌药并实施有效的抗真菌药物管理计划。

要点

  • 广泛皮肤癣菌病且治疗抵抗或近期旅行者,应考虑分子诊断确认印度毛癣菌。
  • 特比萘芬耐药与角鲨烯环氧化酶单核苷酸变异相关。
  • 特比萘芬与伊曲康唑选择存在挑战,需合理处方并实施抗真菌药物管理。

核心结论

  • 印度毛癣菌是新兴皮肤癣菌,因传染性和抗真菌耐药而受全球关注。
  • 需改善诊断可及性、合理处方抗真菌药并实施抗真菌药物管理计划。

研究设计与样本

  • 范围综述,纳入印度毛癣菌的临床和实验室评估。

主要发现

  • 印度毛癣菌对特比萘芬、灰黄霉素及三唑类(氟康唑、伊曲康唑、伏立康唑、泊沙康唑)耐药。
  • 特比萘芬敏感性谱与角鲨烯环氧化酶单核苷酸变异相关。
  • 无分子诊断方法无法将印度毛癣菌与须癣毛癣菌复合群其他成员区分。

关键数值与推荐

  • 广泛皮肤癣菌病、治疗抵抗和/或近期旅行者,应考虑分子诊断确认印度毛癣菌感染。
  • 特比萘芬因耐药受限,伊曲康唑受吸收不稳定、药物相互作用、副作用及部分耐药限制。
  • 正在研究的新疗法包括超生物利用度伊曲康唑、第三代三唑类(伏立康唑、泊沙康唑)及局部-口服联合方案。

临床怎么用

  • 对广泛皮肤癣菌病且治疗抵抗或近期旅行者,考虑分子诊断确认印度毛癣菌。
  • 选择特比萘芬或伊曲康唑时需权衡耐药、吸收、相互作用和副作用。
  • 实施抗真菌药物管理计划,促进合理处方。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There has been a recent shift in the epidemiology of superficial fungal infections (tinea, dermatophytosis, dermatomycoses). Trichophyton indotineae is an emerging dermatophyte species of significant global concern for its contagious nature and antifungal drug resistance. This scoping review includes available clinical and laboratory assessments of T. indotineae to provide a comprehensive up-to-date overview of its epidemiology, clinical manifestations, diagnostic approaches, antifungal susceptibility patterns, resistance mechanisms and management strategies. We discuss T. indotineae resistance against standard and newer antifungals (terbinafine, griseofulvin and triazoles including fluconazole, itraconazole, voriconazole and posaconazole). In particular, the terbinafine susceptibility profile of T. indotineae can be linked to squalene epoxidase (SQLE) single-nucleotide variations. For diagnosis, it is not possible to separate T. indotineae from other members of the T. mentagrophytes complex (T. mentagrophytes and T. interdigitale) without access to molecular diagnostic methods. So, in patients presenting with extensive dermatophytoses, with a history of treatment resistance and/or recent travel, molecular diagnosis to confirm T. indotineae infection should be considered. Healthcare providers often face challenges in choosing between terbinafine and itraconazole treatments. While the use of terbinafine is limited due to resistance, itraconazole is hindered by erratic absorption, possible drug interactions and side effects as well as resistance in some cases. Newer treatments being investigated include super-bioavailable itraconazole, third-generation triazoles (voriconazole, posaconazole) and topical-oral combination regimens. The need for improved diagnostic accessibility, judicious antifungal prescribing, and implementing an effective antifungal stewardship program are highlighted.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Gupta AK, Susmita, Nguyen HC, et al. Trichophyton indotineae: Epidemiology, antifungal resistance and antifungal stewardship strategies. J Eur Acad Dermatol Venereol. 2025. PMID: 40613321. doi:10.1111/jdv.20810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。